Breast Cancer | Unmet Need | US/EU: Advanced/Metastatic Triple-Negative Breast Cancer | 2017
There are limited treatment options for patients with advanced/metastatic, triple-negative breast cancer because commonly used treatments in other breast cancer segments (i.e., hormonal therapies and HER2-targeted therapies) are ineffective in this disease subset. Hence, a high unmet need exists for efficacious targeted therapies for this patient population. Several novel therapies are in development for advanced/metastatic, triple-negative breast cancer; however, historically, it has been difficult for agents to improve outcomes for this hard-to-treat population. Our content examines key drivers of prescribing in this indication and analyses of significant commercial opportunities.
Related Market Assessment Reports
Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
